Trial Profile
A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults with Chronic Hepatitis B (CHB) Infection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 08 May 2013 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Feb 2013 Planned End Date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.